NOVOSEVEN
NOVO NORDISK
Identification
- Active ingredient (INN)
- EPTACOG ALFA (ACTIVE)
- Internal code
- 12 J 160
- Country of Origin
- Denmark
- Pharmaceutical form
- Lyophilised Powder + Solvent for Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1fl. de pdre. + 1fl. de solvt.
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Recombinant human coagulation Factor
VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.
NovoSeven is a vitamin
K-dependent glycoprotein consisting of 406 amino acid residues.
Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indications
For treatment of hemorrhagic complications in hemophilia A and B.
Pharmacodynamics
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa.
Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.